Roche posted higher first-quarter sales that beat analysts’ expectations on higher demand for its key drugs. The Swiss ...

A key player in the U.S. government's battle to combat the flow of deadly fentanyl is a team at a little-known research lab ...

Roche posted higher first-quarter sales that beat analysts' expectations on higher demand for its key drugs. The Swiss pharmaceutical giant said Thursday that sales rose to 15.44 billion Swiss ...

(Find the latest EPS estimates and surprises on Zacks Earnings Calendar) Revenues in the first quarter were driven by robust sales of key drugs Rinvoq, Skyrizi, Venclexta and Vraylar, coupled with ...

Roche posted higher-than-expected first-quarter sales, driven by robust demand for its key drugs, as the company takes active steps to preempt looming U.S. import tariffs. To strengthen its U.S ...

Swiss pharma giant Roche Holding AG RHHBY posted strong growth in the first quarter of 2025. Sales increased 7% year over year to CHF 15.4 billion and were up 6% at constant exchange rates (CER).